Nanobiotix EBIT

Nanobiotix (NBTX) currently reports a EBIT of $-62M as of December 2025. That compares with $-42M in the prior-year period — down 48.5% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Nanobiotix's EBIT history and peer comparisons.

Nanobiotix's EBIT decreased from $-42M to $-62M — a 48.5% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nanobiotix's EBIT of $-62M is lower than the Healthcare sector average of $22B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Nanobiotix reported $-62M in EBIT as of December 2025. That compares with $-42M in the prior-year period — down 48.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-62M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Nanobiotix, and consider following NBTX for alerts when major investors trade the stock.